Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Otton

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Life Sciences|February 14, 1983
Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsS V Otton, T Inaba, W Kalow
Clinical Pharmacology and Therapeutics|February 1, 1981
Debrisoquine hydroxylation capacity: problems of assessment in two populationsT Inaba, S V Otton, W Kalow
Clinical Pharmacology and Therapeutics|April 1, 1980
Deficient metabolism of debrisoquine and sparteineT Inaba, S V Otton, W Kalow
Experientia|September 15, 1984
High affinity of quinidine for a stereoselective microsomal binding site as determined by a radioreceptor assayS V Otton, W Kalow, P Seeman
Life Sciences|January 2, 1984
Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugsS V Otton, T Inaba, W Kalow
British Journal of Clinical Pharmacology|May 1, 1986
A simple borohydride/GC method for measuring sparteine metabolites in manT Inaba, A Vinks, S V Otton
British Journal of Clinical Pharmacology|June 1, 1986
Sparteine oxidation polymorphism: a family studyK Brøsen, S V Otton, L F Gram
Acta Pharmacologica Et Toxicologica|November 1, 1985
Sparteine oxidation polymorphism in DenmarkK Brøsen, S V Otton, L F Gram
Clinical Pharmacology and Therapeutics|November 1, 1986
Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotypeK Brøsen, S V Otton, L F Gram
NIDA Research Monograph|January 1, 1997
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuseE M Sellers, S V Otton, R F Tyndale
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Life Sciences|February 14, 1983
Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsS V Otton, T Inaba, W Kalow
Clinical Pharmacology and Therapeutics|February 1, 1981
Debrisoquine hydroxylation capacity: problems of assessment in two populationsT Inaba, S V Otton, W Kalow
Clinical Pharmacology and Therapeutics|April 1, 1980
Deficient metabolism of debrisoquine and sparteineT Inaba, S V Otton, W Kalow
Experientia|September 15, 1984
High affinity of quinidine for a stereoselective microsomal binding site as determined by a radioreceptor assayS V Otton, W Kalow, P Seeman
Life Sciences|January 2, 1984
Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugsS V Otton, T Inaba, W Kalow
British Journal of Clinical Pharmacology|May 1, 1986
A simple borohydride/GC method for measuring sparteine metabolites in manT Inaba, A Vinks, S V Otton
British Journal of Clinical Pharmacology|June 1, 1986
Sparteine oxidation polymorphism: a family studyK Brøsen, S V Otton, L F Gram
Acta Pharmacologica Et Toxicologica|November 1, 1985
Sparteine oxidation polymorphism in DenmarkK Brøsen, S V Otton, L F Gram
Clinical Pharmacology and Therapeutics|November 1, 1986
Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotypeK Brøsen, S V Otton, L F Gram
NIDA Research Monograph|January 1, 1997
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuseE M Sellers, S V Otton, R F Tyndale
Pageof 4